← Eichor
Condition: Who Grade 3 Glioma Synced from ClinicalTrials.gov · July 29, 2026

Recruiting studies: Who Grade 3 Glioma

Studies currently listed as recruiting on the public registry for this search term. Each page explains the study in plain language, with locations and the study team's contact details. Clinicians: generate a printable list for your patient →

A Study of the Drugs Selumetinib vs. Carboplatin and Vincristine in Patients With Low-Grade Glioma
Phase 3 · 132 location(s) · National Cancer Institute (NCI) · NCT04166409Combination Therapy for the Treatment of Diffuse Midline Gliomas
Phase 2 · 32 location(s) · University of California, San Francisco · NCT05009992Study of Olutasidenib and Temozolomide in HGG
Phase 2 · 20 location(s) · Rigel Pharmaceuticals · NCT06161974Testing the Anti-cancer Drug Erdafitinib for Brain Cancers That Have Returned or Progressed Following Treatment
Phase 2 · 27 location(s) · National Cancer Institute (NCI) · NCT05859334ONC206 for Treatment of Newly Diagnosed, Recurrent Diffuse Midline Gliomas, and Other Recurrent Malignant CNS Tumors
Phase 1 · 7 location(s) · Sabine Mueller, MD, PhD · NCT04732065Anti-GARP Chimeric Antigen Receptor T Cell Therapy for the Treatment of Recurrent Grade III or IV Gliomas
Phase 1 · 1 location(s) · Ohio State University Comprehensive Cancer Center · NCT06964737Triapine in Combination With Temozolomide for the Treatment of Patients With Recurrent Glioblastoma
Phase 1 · 1 location(s) · Northwestern University · NCT06410248Trametinib and Everolimus for Treatment of Pediatric and Young Adult Patients With Recurrent Gliomas (PNOC021)
Phase 1 · 17 location(s) · University of California, San Francisco · NCT04485559Serial MR Imaging and MR Spectroscopic Imaging for the Characterization of Lower Grade Glioma
Phase 1 · 1 location(s) · Susan Chang · NCT04540107Prospective Surgical Study on the Pattern of Electrical Activity in High Grade Glioma as a Predictor of Progression
Phase 1 · 1 location(s) · Case Comprehensive Cancer Center · NCT05565118Targeted Pediatric High-Grade Glioma Therapy
Phase N/A · 21 location(s) · Nationwide Children's Hospital · NCT05839379A Study of RNA-lipid Particle (RNA-LP) Vaccines for Newly Diagnosed Pediatric High-Grade Gliomas (pHGG) and Adult Gliobl
Phase 1 · 2 location(s) · University of Florida · NCT04573140Phase III Clinical Trial Evaluating the Resection Efficacy of 5-Aminolevulinic Acid Hydrochloride (5-ALA HCl) Fluorescen
Phase 3 · 2 location(s) · Lee's Pharmaceutical Limited · NCT06160492Customized Neuro-Imaging Referenced Symptom Video for the Reduction of Patient and Caregiver Anxiety Around Radiation Tr
NA · 1 location(s) · M.D. Anderson Cancer Center · NCT04479696Local, Targeted Therapy With Alpha Emitter [225Ac]Ac-DOTA-SP (TAT) in Glioma (WHO G3-G4) Progression
NA · 2 location(s) · Medical University of Warsaw · NCT06975332Chronic CED of TPT for Recurrent Malignant Glioma
Phase 1 · 1 location(s) · Jeffrey N. Bruce · NCT06666712Safety and Efficacy Study for DC Vaccine in Recurrent or Progressive High-grade Gliomas
Phase 1 · 1 location(s) · Beijing Tiantan Hospital · NCT06253234A Study of Debio 0123 in Combination With Temozolomide in Adult Participants With Recurrent or Progressive Glioblastoma
Phase 1/Phase 2 · 16 location(s) · Debiopharm International SA · NCT05765812An Investigational Scan (Ga-68 PSMA-11 PET/CT) for Detection of Disease Recurrence or Progression in Patients With Gliom
Phase 2 · 1 location(s) · Mayo Clinic · NCT06444412Study of Ribociclib and Everolimus in HGG and DIPG or Ribociclib and Temozolomide in DHG, H3G34-mutant
Phase 2 · 20 location(s) · Nationwide Children's Hospital · NCT05843253Chemotherapy and Radiation Therapy for the Treatment of IDH Wildtype Gliomas or Non-histological (Molecular) Glioblastom
Phase 2 · 1 location(s) · M.D. Anderson Cancer Center · NCT04623931Lorlatinib for Newly-Diagnosed High-Grade Glioma With ROS or ALK Fusion
EARLY_Phase 1 · 18 location(s) · Nationwide Children's Hospital · NCT06333899
Look up another condition
Patient organization or foundation? You can brand this page for your community — your logo, your resources, same honest registry data, kept current daily. Ask about branding →

This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.